Distinguished in Waldenstrom Macroglobulinemia

Dr. Rachid C. Baz

Hematology Oncology | Hematology | Oncology
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
2590 Healing Way, 200 Moffitt Wesley Chapel, 
Wesley Chapel, FL 
Accepting New Patients
Offers Telehealth
Distinguished in Waldenstrom Macroglobulinemia
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
2590 Healing Way, 200 Moffitt Wesley Chapel, 
Wesley Chapel, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rachid Baz is a Hematologist Oncology specialist and a Hematologist in Wesley Chapel, Florida. Dr. Baz is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration. Dr. Baz is currently accepting new patients.

His clinical research consists of co-authoring 100 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Waldenstrom Macroglobulinemia.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
SummaCare
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
2590 Healing Way, 200 Moffitt Wesley Chapel, Wesley Chapel, FL 33543
Other Locations
H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
10901 Mckinley Dr, Tampa, FL 33612
H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug, Other
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: Carfilzomib, Dexamethasone, Telaglenastat
Study Phase: Phase 1
Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill, Bortezomib Injection
Study Phase: Phase 2
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Drug
Study Drugs: Selinexor, Liposomal Doxorubicin, Dexamethasone
Study Phase: Phase 1/Phase 2
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: November 14, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: Survivin Vaccine, Prevnar 13, Granulocyte-colony Stimulating Factor
Study Phase: Early Phase 1
Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Enrollment Status: Completed
Publish Date: November 04, 2022
Intervention Type: Drug, Procedure
Study Drugs: Selinexor, Melphalan, Dexamethasone, Fosaprepitant
Study Phase: Phase 1/Phase 2
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: November 01, 2022
Intervention Type: Drug
Study Drug: Panobinostat
Study Phase: Phase 2
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: APR-246, Azacitidine
Study Phase: Phase 1/Phase 2
Phase I-II Study of Carfilzomib, Lenalidomide, Dexamethasone, and Panobinostat, Ca-R-Pa-Diem, as Induction Therapy for Newly Diagnosed, Untreated, Transplant-Eligible, Multiple Myeloma Patients
Phase I-II Study of Carfilzomib, Lenalidomide, Dexamethasone, and Panobinostat, Ca-R-Pa-Diem, as Induction Therapy for Newly Diagnosed, Untreated, Transplant-Eligible, Multiple Myeloma Patients
Enrollment Status: Withdrawn
Publish Date: April 25, 2017
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 10 Less Clinical Trials

100 Total Publications

Genomics Define Malignant Transformation in Myeloma Precursor Conditions.
Genomics Define Malignant Transformation in Myeloma Precursor Conditions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 08, 2025
Similar Doctors
Celeste M. Bello
Advanced in Waldenstrom Macroglobulinemia
Dr. Celeste M. Bello
Hematology Oncology | Hematology | Oncology
Advanced in Waldenstrom Macroglobulinemia
Dr. Celeste M. Bello
Hematology Oncology | Hematology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (10.0 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Celeste Bello is a Hematologist Oncology specialist and a Hematologist in Tampa, Florida. Dr. Bello is rated as an Elite provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Bello is currently accepting new patients.

Mary M. Li
Advanced in Waldenstrom Macroglobulinemia
Dr. Mary M. Li
Oncology | Hematology
Advanced in Waldenstrom Macroglobulinemia
Dr. Mary M. Li
Oncology | Hematology

Florida Cancer Specialists And Research Institute, LLC

7154 Medical Ctr Dr, 
Spring Hill, FL 
 (25.5 miles away)
352-596-1926
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Mary Li is an Oncologist and a Hematologist in Spring Hill, Florida. Dr. Li is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Paget Disease of the Breast, Waldenstrom Macroglobulinemia, and Breast Cancer. Dr. Li is currently accepting new patients.

Advanced in Waldenstrom Macroglobulinemia
Dr. Julio C. Chavez
Hematology Oncology | Oncology
Advanced in Waldenstrom Macroglobulinemia
Dr. Julio C. Chavez
Hematology Oncology | Oncology
12902 Magnolia Dr, 
Tampa, FL 
 (9.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Julio Chavez is a Hematologist Oncology specialist and an Oncologist in Tampa, Florida. Dr. Chavez is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Primary Lymphoma of the Brain, Follicular Lymphoma, and Bone Marrow Aspiration. Dr. Chavez is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baz's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 11 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile